Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

被引：0
|
作者：
S Redaelli
F Boschelli
P Perini
A Pirola
M Viltadi
C Gambacorti-Passerini
机构：
[1] University of Milano-Bicocca,Department of Clinical Medicine and Prevention
[2] S.Gerardo Hospital,undefined
[3] Center for Integrative Biology and Therapeutics,undefined
[4] Pfizer Research,undefined
[5] Pearl River,undefined
[6] NY,undefined
[7] USA. E-mail carlo.gambacorti@unimib.it,undefined
来源：
Leukemia | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1223 / 1227
页数：4
相关论文
共 50 条
  • [1] Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib
    Redaelli, S.
    Boschelli, F.
    Perini, P.
    Pirola, A.
    Viltadi, M.
    Gambacorti-Passerini, C.
    LEUKEMIA, 2010, 24 (06) : 1223 - 1227
  • [2] Synergistic activity of the novel Src/AbI inhibitor bosutinib in combination with imatinib
    Redaelli, Slara
    Boschelli, Frank
    Viltadi, Michela
    Meneghetti, Iris
    Gambacorti, Carlo
    BLOOD, 2007, 110 (11) : 861A - 861A
  • [3] Novel Src/ Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/ Abl signaling
    Bieerkehazhi, Shayahati
    Chen, Zhenghu
    Zhao, Yanling
    Yu, Yang
    Zhang, Huiyuan
    Vasudevan, Sanjeev A.
    Woodfield, Sarah E.
    Tao, Ling
    Yi, Joanna S.
    Muscal, Jodi A.
    Pang, Jonathan C.
    Guan, Shan
    Zhang, Hong
    Nuchtern, Jed G.
    Li, Hui
    Li, Huiwu
    Yang, Jianhua
    ONCOTARGET, 2017, 8 (01) : 1469 - 1480
  • [4] Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia
    Keller, Gunhild
    Schafhausen, Philippe
    Brummendorf, Tim H.
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (05) : 489 - 497
  • [5] Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
    El Rassi, Fuad
    Khoury, Hanna Jean
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2013, 6 : 57 - 62
  • [6] Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia
    Keller-v. Amsberg, Gunhild
    Bruemmendorf, Tim H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1121 - 1127
  • [7] Inhibition of migration in gastrointestinal cancer cells by subtoxic concentrations of the dual src and abl inhibitor bosutinib
    Mueller, S.
    Kalwa, H.
    Jenke, R. G.
    Lordick, F.
    Aigner, A.
    Buech, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 313 - 313
  • [8] Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
    Redaelli, Sara
    Piazza, Rocco
    Rostagno, Roberta
    Magistroni, Vera
    Perini, Pietro
    Marega, Manuela
    Gambacorti-Passerini, Carlo
    Boschelli, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 469 - 471
  • [9] In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic
    Puttini, Miriam
    Coluccia, Addolorata M. L.
    Boschelli, Frank
    Franceschino, Anna
    Tomaghi, Lucia
    Ahmed, Shaheen
    Redaelli, Sara
    Piazza, Rocco
    Magistroni, Vera
    Andreoni, Federica
    Scapozza, Leonardo
    Formelli, Franca
    Gambacorti, Carlo
    BLOOD, 2006, 108 (11) : 617A - 617A
  • [10] A Src/Abl kinase inhibitor, bosutinib, downregulates and inhibits PARP enzyme and sensitizes cells to the DNA damaging agents
    Kirmizibayrak, Petek Ballar
    Ilhan, Recep
    Yilmaz, Sinem
    Gunal, Selin
    Tepedelen, Burcu Erbaykent
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2018, 43 (02): : 101 - 109
12345